Please use this identifier to cite or link to this item: http://repository.i3l.ac.id/jspui/handle/123456789/536
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGotama, Karen Saphira-
dc.date.accessioned2022-09-16T06:13:51Z-
dc.date.available2022-09-16T06:13:51Z-
dc.date.issued2022-06-02-
dc.identifier.urihttp://repository.i3l.ac.id/jspui/handle/123456789/536-
dc.description.abstractThe COVID-19 pandemic is a worldwide threat caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This highly contagious virus has dramatically impacted the world’s demographics, including Indonesia. Some method to reduce the number of COVID-19 is by developing and implementing vaccination programs. Peptide-based vaccines, especially those developed based on the T-cell epitopes, could be the solution for the emergence of SARS-CoV-2 variants. Here, the development of T-cell epitope-based vaccines will use immunoinformatic tools. It starts with obtaining the Indonesian SARS-CoV-2 sequences and the Indonesian HLA allele. Using IEDB tools, epitopes for MHC class I, class II, and B cells were acquired. The epitopes were evaluated based on several criteria: immunogenicity, IFNγ inducing ability for MHC class II, promiscuity in HLA alleles, conservancy analysis, and homology analysis to the human proteome. Several epitopes were chosen as VC which are six of MHC class I, four of MHC II, and three of B cells epitopes which were linked using li nkers. Once again, it was evaluated based on having antigenicity, allergenicity, toxicity, and having a good physicochemical characteristic like pI, half-life, good stability, good GRAVY score, high population coverage, and non-homologous to human microbiome. The final vaccine construct consisted of 249 AA sequences with coverage of 99% in Indonesia. Lastly, the interaction between TLR4 was evaluated and visualized. With this, specialized vaccines -that are highly specific, eliciting long-lasting adaptive immunity, and did not have unwanted immune responses- for the Indonesian population could be developed.en_US
dc.language.isoenen_US
dc.publisherIndonesia International Institute for Life Sciencesen_US
dc.relation.ispartofseriesT202207035;BM 22-033-
dc.subjectCOVID-19en_US
dc.subjectPandemicen_US
dc.subjectSARS-CoV-2en_US
dc.subjectepitopesen_US
dc.titleIn silico Analysis of SARS-CoV-2 T Cell Epitope-Based Vaccine Design for Indonesian Populationen_US
dc.typeThesisen_US
Appears in Collections:Biomedicine

Files in This Item:
File Description SizeFormat 
BM 22-033 Karen Saphira Gotama.pdf
  Restricted Access
Full Text1.15 MBAdobe PDFView/Open Request a copy
Chapter 1.pdfChapter 1195.13 kBAdobe PDFView/Open
Cover.pdfCover112.44 kBAdobe PDFView/Open
References.pdfReferences180.01 kBAdobe PDFView/Open
Abstract.pdfAbstract165.18 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.